MeMed BV

Distinguish between bacterial and viral infections in 15 minutes

Component 256 – 2@2x

Is it a bacterial or viral infection?

Since bacterial and viral infections are clinically indistinguishable, physicians are often challenged to decide whether to treat with antibiotics or not. By providing rapid, accurate host response information to differentiate bacterial and viral infections, MeMed BV® helps physicians to make faster, more informed decisions about how and when to treat.

Diagnostic uncertainty leads to antibiotic misuse

antibiotic overuse1
antibiotic underuse2

Conventional tests are often insufficient because…

Inaccessible infection sites

Often no pathogens are detected

False alarms due to colonization

Prolonged time to results

Poor performance for emerging pathogens

Three Biomarkers + Machine Learning = MeMed BV

In 15 minutes from a small serum sample, the FDA-cleared MeMed BV computationally integrates the levels of three host immune proteins – TRAIL, IP-10 and CRP – into a simple score indicating the likelihood of a bacterial immune response or co-infection versus a likely viral immune response.

AUC3

MeMed BV Performance

The FDA clinical study (Apollo) was conducted to establish the diagnostic performance of the MeMed BV test for differentiating bacterial from viral infection in patients with suspected acute bacterial or viral infection.3

Our unique emphasis on quality and breadth of clinical evidence sets MeMed apart. MeMed BV performance has been validated in multi-national, double-blind clinical studies and real world real world settings enrolling almost 20,000 subjects in Europe, Israel and the United States.3-9 These studies have consistently demonstrated compelling performance results in different clinical settings, age groups, and patients with different clinical syndromes.

>20K

MeMed BV performance goals independently confirmed in unprecedented validation and real-world usage encompassing >20,000 patients.3-9

Interpreting Results

V(Viral/ other)

B(Bacterial)

0 10 35 65 90 100

0 ≤ score ≤ 10
High likelihood of viral infection (or other non-bacterial etiology)

10 < score < 35
Moderate likelihood of viral infection (or other non-bacterial etiology)

35 ≤ score ≤ 65 Equivocal

65 < score < 90
Moderate likelihood of bacterial infection (or co-infection)

90 ≤ score ≤ 100
High likelihood of bacterial infection (or co-infection)

Looking for a quick guide to the MeMed BV score?

Download the Pocket Guide

    Thank you!

    Toggle content

    How Does it Work?

    Play video

    References

    1. Centers for Disease Control and Prevention. Antibiotic use in the United States: Progress and opportunities, 2018 update. Centers for Disease Control and Prevention, Atlanta, GA. 2018.
    2. Kornblith AE, Fahimi J, Kanzaria HK, Wang RC. Predictors for under-prescribing antibiotics in children with respiratory infections requiring antibiotics. Am J Emerg Med. 2018 Feb;36(2):218-225. doi: 10.1016/j.ajem.2017.
    3. MeMed data on file. Apollo Clinical Study (NCT04690569) conducted to establish the diagnostic performance of the MeMed BV test for differentiating bacterial from viral infection in patients with suspected acute bacterial or viral infection
    4. Oved K, Cohen A, Boico O, Navon R, Friedman T, Etshtein L, et al. A novel host-proteome signature for distinguishing between acute bacterial and viral infections. PloS One. 2015 Mar 18;10(3):e0120012.
    5. van Houten CB, de Groot JA, Klein A, Srugo I, Chistyakov I, de Waal W, et al. A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): A double-blind, multicentre, validation study. Lancet Infect Dis. 2017 Apr 1;17(4):431-40.
    6. Srugo I, Klein A, Stein M, Golan-Shany O, Kerem N, Chistyakov I, et al. Validation of a novel assay to distinguish bacterial and viral infections. Pediatrics. 2017 Oct 1;140(4).
    7. Ashkenazi-Hoffnung L, Oved K, Navon R, Friedman T, Boico O, Paz M, et al. A host-protein signature is superior to other biomarkers for differentiating between bacterial and viral disease in patients with respiratory infection and fever without source: A prospective observational study. Eur J Clin Microbiol Infect Dis. 2018 Jul;37(7):1361-71.
    8. Stein M, Lipman-Arens S, Oved K, Cohen A, Bamberger E, Navon R, et al. A novel host-protein assay outperforms routine parameters for distinguishing between bacterial and viral lower respiratory tract infections. Diagn Microbiol Infect Dis. 2018 Mar 1;90(3):206-13.
    9. Eden E, Srugo I, Gottlieb T, Navon R, Boico O, Cohen A, et al. Diagnostic accuracy of a TRAIL, IP-10 and CRP combination for discriminating bacterial and viral etiologies at the Emergency Department. J Infect. 2016 Aug 1;73(2):177-80.
    10. The Rosetta study. Data on file.
    11. Papan C, Argentiero A, Porwoll M, Hakim U, Farinelli E, Testa I, et al. A host signature based on TRAIL, IP-10, and CRP for reducing antibiotic overuse in children by differentiating bacterial from viral infections: A prospective, multicentre cohort study. Clin Microbiol Infect. 2022 May 1;28(5):723-30.
    12. The Observer study. Data on file.
    Toggle content

    Contact Us

    7 Nahum Het St., Tirat Carmel
    Park High-Tech North, 3508506, Israel
    +972-4-8500302 200 Brickstone Sq., Ste.106
    Andover, MA 01801, USA
    +1-888-396-0030

      Thank you!

      Your submission has been sent